<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069598</url>
  </required_header>
  <id_info>
    <org_study_id>A-HIT 4-SI Study</org_study_id>
    <nct_id>NCT04069598</nct_id>
  </id_info>
  <brief_title>Statin Intolerance in Patients With Myocardial Infarction</brief_title>
  <official_title>Statin Intolerance in Patients With Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turkish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turkish Society of Cardiology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute coronary syndrome (MI, NSTEMI, USAP) will be included. They will be
      screened for statin intolernace for 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Statin intolerance</measure>
    <time_frame>6 months</time_frame>
    <description>Number (percentage) of patients with statin intolerance</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Statin Adverse Reaction</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Statin intolerance test</intervention_name>
    <description>Statin intolerance test</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Acute coronary syndrome patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute coronary syndrome

        Exclusion Criteria:

          -  Being on statin, having statin related side effects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Haseki</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umit Y Sinan</last_name>
      <phone>0212) 459 20 00</phone>
      <email>drumityasar@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siyami Ersek</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barış Güngör</last_name>
      <phone>+90(216) 542 44 44</phone>
      <email>barisgungor@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tepecik</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oner Ozdogan</last_name>
      <phone>+90 232 469 69 69</phone>
      <email>onerozdogan@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ozcan Basaran</name>
      <address>
        <city>Mugla</city>
        <zip>48000</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ozcan Basaran</last_name>
      <phone>+905065359013</phone>
      <email>basaran_ozcan@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

